Chemours (Wilmington, Delaware) reports net income for the third quarter of $204 million, swinging from a loss of $29 million in the year-ago period. Net sales totaled $1.398 billion, down 5.9% year-over-year (YOY), mainly the result of divestitures, says the company. Adjusted earnings per share were $0.61, up 52% YOY and well above the analysts’ consensus of $0.35. Adjusted EBITDA totaled $268 million, up 59% YOY as cost reductions, improved average prices in titanium technologies, and improved profitability in fluoroproducts were partially offset by divestitures within chemical solutions....